Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPARalpha in atherosclerosis and inflammation.

Fokko Zandbergen1, Jorge Plutzky

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 742, Boston, MA 02115, USA.

Biochimica Et Biophysica Acta
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Circulation. Population health and outcomes·2026
Same author

Engagement and Weight Change in an Online Weight Management Program in Clinical Settings: An Implementation Project.

Journal of general internal medicine·2026
Same author

Enhanced peripheral tissue oxygenation and hemoglobin concentration after a high-fat meal measured with spatial frequency domain imaging.

Biophotonics discovery·2026
Same author

Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial.

Clinical cardiology·2026
Same author

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Nature medicine·2026
Same author

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Endocrine connections·2026

Peroxisome proliferator-activated receptor (PPAR)alpha, activated by fatty acids and fibrates, regulates lipid metabolism and inflammation. It impacts atherosclerosis by reducing leukocyte adhesion and foam cell formation, potentially improving cardiovascular health.

Area of Science:

  • Molecular biology
  • Cardiovascular research
  • Metabolic diseases

Background:

  • Peroxisome proliferator-activated receptor (PPAR)alpha is a nuclear receptor activated by ligands like fatty acids and fibrates.
  • PPARalpha regulates genes involved in lipid metabolism, fatty acid oxidation, and glucose homeostasis.
  • PPARalpha also exhibits anti-inflammatory effects in the vascular wall and liver.

Purpose of the Study:

  • To provide an overview of the mechanisms by which PPARalpha influences atherosclerosis initiation and progression.
  • To emphasize the role of PPARalpha in modulating atherosclerosis-associated inflammatory responses.
  • To discuss the clinical implications and ongoing research regarding PPARalpha and cardiovascular health.

Main Methods:

  • Literature review and synthesis of existing research on PPARalpha.

Related Experiment Videos

  • Analysis of PPARalpha's effects on cellular and molecular pathways relevant to atherosclerosis.
  • Examination of clinical trial data concerning PPARalpha agonists (fibrates).

    • Main Results:

    • PPARalpha activation inhibits early atherosclerosis by reducing leukocyte adhesion and migration.
    • PPARalpha activation hinders foam cell formation in later stages by regulating cholesterol transport and oxidative stress.
    • PPARalpha may enhance plaque stability and reduce thrombogenicity, though clinical benefits of fibrates are debated.

    Conclusions:

    • PPARalpha plays a crucial role in regulating lipid metabolism, inflammation, and atherosclerosis.
    • PPARalpha activation demonstrates multifaceted protective effects against atherosclerosis development and progression.
    • Further research is needed to clarify the clinical utility of PPARalpha modulation for cardiovascular event reduction.